HLA-DRB1∗16:01-DQB1∗05:02 is a novel genetic risk factor for flupirtine-induced liver injury

Pharmacogenetics and Genomics

Volumn 26, Issue 5, 2016, Pages 218-224

  Nicoletti, Paola ^a   Werk, Anneke N ^e   Sawle, Ashley ^b   Shen, Yufeng ^a   Urban, Thomas J ^c   Coulthard, Sally A ^g   Bjornsson, Einar S ⁱ   Cascorbi, Ingolf ^e   Floratos, Aris ^a   Stammschulte, Thomas ^f   Gundert Remy, Ursula ^f   Nelson, Matthew R ^d   Aithal, Guruprasad P ^h   Daly, Ann K ^g  

^a Department of Systems Biology ^*  (United States)

^b Howard Hughes Medical Institute   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d GLAXOSMITHKLINE   (United States)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f Drug Commission of the German Medical Association (DCGMA)   (Germany)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h NIHR NOTTINGHAM BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

ⁱ LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

Adverse drug reaction; Flupirtine; Genome wide association study; Hepatotoxicity; HLA allele; Pharmacogenomics

Indexed keywords

DICLOFENAC; DIPYRONE; DNA; FLUPIRTINE; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE P1; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 05:02 ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 16:01 ANTIGEN; HLA DRB1 ANTIGEN; NAT2 PROTEIN; PROTEIN; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; HLA DQ ANTIGEN; HLA-DQB1 ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GERMANY; HAPLOTYPE; HETEROZYGOSITY; HLA SYSTEM; HLA TYPING; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MIDDLE AGED; PHARMACOGENETICS; POPULATION STRUCTURE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TOXIC HEPATITIS; CHEMICAL AND DRUG INDUCED LIVER INJURY; GENETICS; GENOME-WIDE ASSOCIATION STUDY;

ADULT; AGED; AMINOPYRIDINES; CHEMICAL AND DRUG INDUCED LIVER INJURY; FEMALE; GENOME-WIDE ASSOCIATION STUDY; HLA-DQ BETA-CHAINS; HLA-DRB1 CHAINS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84960155823     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000209     Document Type: Article

References (41)

1. 2+ block via activation of voltage independent potassium channels. Rapid communication. J Neural Transm (Vienna) 1999; 106 (9-10):857-867.
2. Puls F, Agne C, Klein F, Koch M, Rifai K, Manns MP, et al. Pathology of flupirtine-induced liver injury: a histological and clinical study of six cases. Virchows Arch 2011; 458:709-716.
3. Anderson N, Borlak J. Correlation versus causation? Pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting. PLoS One 2011; 6:e25221.
4. Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Orzechowski HD, et al. Flupirtine-induced liver injury-seven cases from the Berlin case-control surveillance study and review of the German spontaneous adverse drug reaction reporting database. Eur J Clin Pharmacol 2014; 70:453-459.
5. Michel MC, Radziszewski P, Falconer C, Marschall-Kehrel D, Blot K. Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years. Br J Clin Pharmacol 2012; 73:821-825.
6. Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Sarganas G, et al. Drug-induced liver injury: results from the hospital-based Berlin case-control surveillance study. Br J Clin Pharmacol 2015; 79:988-999.
7. Methling K, Reszka P, Lalk M, Vrana O, Scheuch E, Siegmund W, et al. Investigation of the in vitro metabolism of the analgesic flupirtine. Drug Metab Dispos 2009; 37:479-493.
8. Siegmund W, Modess C, Scheuch E, Methling K, Keiser M, Nassif A, et al. Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1. Br J Clin Pharmacol 2015; 79:501-513.
9. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011; 89:806-815.
10. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46:1323-1330.
11. Nelson MR, Bryc K, King KS, Indap A, Boyko AR, Novembre J, et al. The Population Reference Sample, POPRES: a resource for population, disease, and pharmacological genetics research. Am J Hum Genet 2008; 83:347-358.
12. Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, Rochon J, et al. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics 2012; 22:784-795.
13. Pirmohamed M, Arbuckle JB, Bowman CE, Brunner M, Burns DK, Delrieu O, et al. Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2007; 8:1661-1691.
14. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 2010; 42:978-984.
15. Daly AK, Steen VM, Fairbrother KS, Idle JR. CYP2D6 multiallelism. Methods Enzymol 1996; 272:199-210.
16. Delaneau O, Zagury JF, Marchini J. Improved whole-chromosome phasing for disease and population genetic studies. Nat Methods 2013; 10:5-6.
17. Marchini J, Howie B. Genotype imputation for genome-wide association studies. Nat Rev Genet 2010; 11:499-511.
18. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009; 5:e1000529.
19. Zheng X, Shen J, Cox C, Wakefield JC, Ehm MG, Nelson MR, Weir BS. HIBAG-HLA genotype imputation with attribute bagging. Pharmacogenomics J 2014; 14:192-200.
20. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38:904-909.
21. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81:559-575.
22. The R Project for Statistical Computing. Available at: http://www.r-project. org [Accessed 3 December 2015].
23. Aithal GP, Nicoletti P, Bjornsson E, Lucena MI, Andrade RJ, Grove J, et al. HLA-A∗33:01 is strongly associated with drug-induced liver injury (DILI) due to terbinafine and several other unrelated compounds. Hepatology 2015; 62:324A-327A.
24. Daly AK. Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations. Drug Metabol Personal Ther 2015; 30:165-174.
25. Kringen MK, Piehler AP, Grimholt RM, Opdal MS, Haug KB, Urdal P. Serum bilirubin concentration in healthy adult North-Europeans is strictly controlled by the UGT1A1 TA-repeat variants. PLoS One 2014; 9:e90248.
26. Urban TJ, Daly AK, Aithal GP. Genetic basis of drug-induced liver injury: present and future. Semin Liver Dis 2014; 34:123-133.
27. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011; 141:338-347.
28. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010; 42:711-714.
29. Noble JA, Valdes AM, Cook M, Klitz W, Thomson G, Erlich HA. The role of HLA class II genes in insulin-dependent diabetes mellitus: molecular analysis of 180 Caucasian, multiplex families. Am J Hum Genet 1996; 59:1134-1148.
30. Hollenbach JA, Oksenberg JR. The immunogenetics of multiple sclerosis: a comprehensive review. J Autoimmun 2015; 64:13-25.
31. Parham LR, Briley LP, Li L, Shen J, Newcombe PJ, King KS, et al. Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1∗07:01. Pharmacogenomics J 2015. [Epub ahead of print].
32. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008; 8:186-195.
33. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, et al. HLA-B∗5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41:816-819.
34. Hirata K, Takagi H, Yamamoto M, Matsumoto T, Nishiya T, Mori K, et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J 2008; 8:29-33.
35. Kim SH, Saide K, Farrell J, Faulkner L, Tailor A, Ogese M, et al. Characterization of amoxicillin-and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury. Hepatology 2015; 62:887-899.
36. Lucena MI, Andrade RJ, Fernández MC, Pachkoria K, Pelaez G, Durán JA, et al. Spanish Group for the Study of Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas a Medicamentos (GEHAM)). Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 2006; 44:850-856.
37. Monshi MM, Faulkner L, Gibson A, Jenkins RE, Farrell J, Earnshaw CJ, et al. Human leukocyte antigen (HLA)-B∗57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 2013; 57:727-739.
38. Illing PT, Vivian JP, Dudek NL, Kostenko L, Chen Z, Bharadwaj M, et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 2012; 486:554-558.
39. Hautekeete ML, Horsmans Y, Van Waeyenberge C, Demanet C, Henrion J, Verbist L, et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999; 117:1181-1186.
40. Lucena MI, Andrade RJ, Kaplowitz N, García-Cortes M, Fernández MC, Romero-Gomez M, et al. Spanish Group for the Study of Drug-Induced Liver Disease. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009; 49:2001-2009.
41. Li C, Ni J, Wang Z, Li M, Gasparic M, Terhaag B, Uberall MA. Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial. Curr Med Res Opin 2008; 24:3523-3530.